Yu Shyr, PhD of Vanderbilt University School of Medicine, Nashville, TN discusses the importance of integrating different data sources, including different types of ‘omics’ data, and in the future; clinical data behavioral data, and environmental data. This data could be combined to create new drug development pathways. Currently, this is not possible due to the amount of data which would be produced and limitations on storage and analysis. integrating different data sources beyond genomics to find new drug development pathways, and what this would imply. Dr Shyr explains subgroup analysis and targeted therapy would still be used, but each patient could be fit for different ‘omics’ pathways to create more targeted therapies. He calls for a broader use of data science and biomarker data. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.